Table 2.
Overall Survival and Progression‐Free Survival Rates of All 50 Patients With High‐Grade Glioma
| Characteristics | No. of Patients | OS (95% CI), % | PFS (95% CI), % | ||||
|---|---|---|---|---|---|---|---|
| 12‐Month OS | 18‐Month OS | P | 12‐Month PFS | 18‐Month PFS | P | ||
| Sex | .705 | .786 | |||||
| Men | 30 | 86.2 (71.7‐100) | 77.2 (55.8‐98.6) | 79.2 (62.5‐95.7) | 54.8 (31.9‐77.7) | ||
| Women | 20 | 83.1 (65.7‐100) | 66.7 (40.6‐91.6) | 68.2 (45.5‐89.1) | 68.2 (45.5‐89.1) | ||
| Age, y | .019 | .060 | |||||
| <50 | 22 | 100 | 92.9 (79.4‐100) | 94.7 (84.7‐100) | 76.7 (52.8‐100) | ||
| ≥50 | 28 | 79.3 (63.2‐95.6) | 60.9 (38.6‐83.2) | 60.0 (40.4‐79.6) | 48.3 (26.7‐69.9) | ||
| Resection degree | .260 | .282 | |||||
| Partial/biopsy | 11 | 86.7 (62.4‐100) | 86.7 (62.4‐100) | 80.4 (56.1‐100) | 80.4 (56.1‐100) | ||
| Subtotal | 22 | 76.7 (56.3‐97.1) | 57.8 (29.8‐85.8) | 69.6 (49.0‐90.2) | 52.2 (26.3‐78.1) | ||
| Total | 17 | 92.0 (76.9‐100) | 79.7 (53.8‐100) | 76.4 (54.4‐98.4) | 57.3 (28.3‐86.3) | ||
| Symptom duration, mo | .531 | .547 | |||||
| >2 | 21 | 94.6 (84.2‐100) | 86.4 (68.4‐100) | 83.8 (66.6‐100) | 60.5 (29.7‐91.3) | ||
| ≤2 | 29 | 78.3 (61.2‐95.4) | 65.7 (44.3‐87.1) | 66.8 (47.8‐85.8) | 56.5 (35.7‐77.3) | ||
| KPS | .022 | .058 | |||||
| >80 | 37 | 85.8 (72.7‐98.9) | 79.5 (62.4‐96.6) | 81.6 (68.1‐95.1) | 72.3 (55.2‐89.4) | ||
| ≤80 | 13 | 81.8 (58.7‐100) | 53.7 (17.0‐90.4) | 64.1 (35.3‐92.9) | 30.5 (0.5‐60.5) | ||
| Histology: WHO grade | .023 | .002 | |||||
| 4 | 34 | 77.4 (61.3‐93.5) | 61.0 (40.0‐82.0) | 61.3 (42.9‐79.7) | 42.7 (22.7‐62.7) | ||
| 3 | 16 | 100 | 100 | 100 | 100 | ||
| IDH gene | .139 | .012 | |||||
| Wild type | 37 | 79.4 (64.5‐94.3) | 62.8 (42.0‐83.6) | 64.7 (47.5‐81.9) | 45.8 (26.0‐65.6) | ||
| Mutant | 13 | 100 | 100 | 100 | 100 | ||
| MGMT promoter | .337 | .058 | |||||
| Methylated | 22 | 94.1 (82.9‐100) | 87.1 (70.4‐100) | 90.8 (70.8‐100.0) | 75.6 (53.8‐97.4) | ||
| Unmethylated/NA | 28 | 82.1 (66.0‐98.2) | 57.6 (30.9‐84.3) | 59.4 (38.2‐80.6) | 45.2 (21.5‐68.9) | ||
| Radiation necrosis | .237 | .978 | |||||
| Yes | 11 | 90.9 (73.8‐100) | 67.8 (36.6‐99.0) | 72.7 (46.4‐99.0) | 60.6 (29.8‐91.4) | ||
| No | 39 | 86.5 (74.0‐99.0) | 75.3 (56.9‐93.7) | 74.5 (58.8‐90.2) | 59.5 (39.9‐79.1) | ||
| Pseudoprogression | .865 | .408 | |||||
| Yes | 7 | 100 | 100 | 100 | 50 (0.0‐100) a | ||
| No | 43 | 83.2 (70.8‐95.5) | 69.9 (52.4‐87.3) | 70.7 (55.8‐85.6) | 59.3 (42.2‐76.4) | ||
Abbreviations: KPS, Karnofsky performance status; MGMT, O‐6‐methylguanine‐DNA methyltransferase; NA, not available; OS, overall survival; PFS, progression‐free survival; WHO, World Health Organization.
a
Only 1 patient had 18‐month follow‐up.